Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002642207 | SCV002962381 | uncertain significance | Methylcobalamin deficiency type cblG | 2022-10-17 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 941 of the MTR protein (p.Gln941Leu). This variant is present in population databases (rs761601954, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with MTR-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MTR protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004065905 | SCV005008086 | uncertain significance | Inborn genetic diseases | 2021-03-26 | criteria provided, single submitter | clinical testing | The c.2822A>T (p.Q941L) alteration is located in exon 27 (coding exon 27) of the MTR gene. This alteration results from a A to T substitution at nucleotide position 2822, causing the glutamine (Q) at amino acid position 941 to be replaced by a leucine (L). The p.Q941L alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |